New preclinical data on M2T-CD33 highlights a novel approach for Acute Myeloid Leukemia. This superantigen-based therapy targets MHC-II, triggering robust anti-leukemic immunity. Notably, it showed synergy with anti-PD-1 and no high-dose toxicity. www.nature.com/articles/s41...

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia - Blood Cancer Journal

Blood Cancer Journal - A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia

nature.com

Excited to share our new paper “MHCquant2 refines immunopeptidomics tumor antigen discovery” in Genome Biology! An open-source @nf-co.re workflow using OpenMS, DeepLC & MS²PIP boosts peptide ID & sensitivity. Scalable, reproducible & ready for large-scale immunopeptidomics. 👉 rdcu.be/eHFTZ

Looking for a new position? Come join our team as new assistant to the department head! Check out the following link for more information: jobs.medizin.uni-tuebingen.de/Job/6025/Ass...

New study presents Mal-ID, an #AI model analyzing BCR/TCR sequences to identify immune states across infections, autoimmune diseases and vaccination. It classifies diseases with high accuracy, reveals immune patterns and highlights #diagnostic potential of sequencing. www.science.org/doi/full/10....

We are #hiring! 🚀 Join our #bioinformatics team in a truly #interdisciplinary environment driving #immunopeptidomics analyses and pipeline development with direct impact on advancing patient treatment! Check out the full job description: jobs.medizin.uni-tuebingen.de/Job/5775/Bio...

Phase I trial update: Our warehouse-based cancer peptide vaccine for CLL showed promising safety but limited T cell responses. Next: Follow-up trial with improved adjuvants & BTK inhibitors underway. Stay tuned! #CancerResearch #Immunopeptidomics #Immunotherapy 🔗 doi.org/10.3389/fimm...

Frontiers | Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

doi.org